Moderna Surges 8% on Unexplained Momentum

Moderna's stock price surged 8% to $147.37 on Friday morning trading, despite no notable news or announcements from the company.

The move comes as Moderna's closest peer in cancer-vaccine development, BioNTech, remained nearly flat at $96.85, while partner Merck slipped into the red by 0.3% to $144.23.

Moderna's recent run has been significant, with a 143% gain over the past month, leaving some investors wondering if the stock is due for a correction or if there are underlying factors driving its momentum.

The lack of news or announcements from Moderna means that positioning and momentum buying are likely key drivers behind the stock's surge, rather than fundamental changes in the company's prospects.